| Study/year . | RVSD definition cut-off-modality . | population . | n . | follow-up . | Main finding . |
|---|---|---|---|---|---|
| Larose et al. 20074 | <40% (CMR) | Patients with recent myocardial infarction (>30 days) | 147 | Median 17 months | RVEF <40% remained a significant independent predictor of mortality after adjusting for LVEF and infarct size (aHR 2.86; P = 0.03) |
| Meyer et al. 20102 | Multiple cut-offs: <40, <30, <20 (Radionuclide ventriculography) | Chronic HFrEF patients from ‘BEST’ trial | 2008 | Mean 2 years | RVSD was independently associated with mortality only at the cut-off <20%, aHR 1.32 (1.02 to 1.71; P = 0.034) |
| Gulati et al. 20138 | <45% (CMR) | Chronic HFrEF patients with dilated NICM | 250 | Median 6.8 years | RVSD was an independent predictor of mortality or cardiac transplant (HR 3.90; 95% CI: 2.16–7.04; P < 0.01) |
| Murninkas et al. 20149 | <38% (Radionuclide angiography) | Stable outpatient HFrEF cohort | 246 | Median 2.7 years | RVSD was not significantly associated with MACE or death after adjusting for LVEF and age |
| Goliasch et al. 201517 | <35% (CMR) | Chronic HFpEF patients | 142 | Median 10 months | RVSD was associated with hospitalization and cardiac death on univariate analysis, but not after adjusting for covariates. |
| Aschauer et al. 201615 | ≤45% (CMR) | Chronic HFpEF patients | 171 | Median 1.5 years | RVSD was an independent predictor of MACE (HR 4.90; 95% CI: 2.46–9.75; P < 0.01) |
| Mikami et al. 201710 | <45% (CMR) | Chronic HFrEF patients (ischaemic and non-ischaemic) | 314 | Median 2.1 years | RVSD was an independent predictor of cardiac arrest and/or ICD implantation (HR = 2.98; P = 0.002) |
| Gill et al. 201911 | <20% (CMR) | HFrEF patients with LVEF ≤35 | 87 | Median 3 years | RVSD was associated with a higher risk of MACE in the NICM subgroup but not ICM subgroup. |
| Purmah et al. 202118 | <40% (CMR) | Broad cardiovascular disease population, mean LVEF 55% | 7131 | Median 2.48 years | RVSD was associated with unadjusted HR of 3.1 for MACE, however it was not statistically significant after adjusting for LVEF |
| Ashcroft et al. 20216 | <46.9% (3D echocardiography) | Patients admitted with acute HF | 418 | Median 2 years | RVSD was associated with increased risk of ACM (HR 1.48; 95% CI 1.09–2.03, P ≤ 0.01) |
| Becker et al. 202112 | <45% (CMR) | Stable patients with dilated cardiomyopathy, mean LVEF 37% [25–44%] | 216 | Median 2.2 years | RVSD was significantly associated with shorter time to the composite of death and ventricular arrhythmias (10% drop in RVEF was associated with 0.81 increase in aHR, P = 0.02) |
| Kanagala et al. 202119 | <47% (CMR) | Chronic HFpEF patients compared against healthy controls | 183 | Median 4 years | RVSD was a strong independent predictor of HFH/ACM (aHR = 3.95, 95% CI: 1.88–8.29, P < 0.001) |
| Study/year . | RVSD definition cut-off-modality . | population . | n . | follow-up . | Main finding . |
|---|---|---|---|---|---|
| Larose et al. 20074 | <40% (CMR) | Patients with recent myocardial infarction (>30 days) | 147 | Median 17 months | RVEF <40% remained a significant independent predictor of mortality after adjusting for LVEF and infarct size (aHR 2.86; P = 0.03) |
| Meyer et al. 20102 | Multiple cut-offs: <40, <30, <20 (Radionuclide ventriculography) | Chronic HFrEF patients from ‘BEST’ trial | 2008 | Mean 2 years | RVSD was independently associated with mortality only at the cut-off <20%, aHR 1.32 (1.02 to 1.71; P = 0.034) |
| Gulati et al. 20138 | <45% (CMR) | Chronic HFrEF patients with dilated NICM | 250 | Median 6.8 years | RVSD was an independent predictor of mortality or cardiac transplant (HR 3.90; 95% CI: 2.16–7.04; P < 0.01) |
| Murninkas et al. 20149 | <38% (Radionuclide angiography) | Stable outpatient HFrEF cohort | 246 | Median 2.7 years | RVSD was not significantly associated with MACE or death after adjusting for LVEF and age |
| Goliasch et al. 201517 | <35% (CMR) | Chronic HFpEF patients | 142 | Median 10 months | RVSD was associated with hospitalization and cardiac death on univariate analysis, but not after adjusting for covariates. |
| Aschauer et al. 201615 | ≤45% (CMR) | Chronic HFpEF patients | 171 | Median 1.5 years | RVSD was an independent predictor of MACE (HR 4.90; 95% CI: 2.46–9.75; P < 0.01) |
| Mikami et al. 201710 | <45% (CMR) | Chronic HFrEF patients (ischaemic and non-ischaemic) | 314 | Median 2.1 years | RVSD was an independent predictor of cardiac arrest and/or ICD implantation (HR = 2.98; P = 0.002) |
| Gill et al. 201911 | <20% (CMR) | HFrEF patients with LVEF ≤35 | 87 | Median 3 years | RVSD was associated with a higher risk of MACE in the NICM subgroup but not ICM subgroup. |
| Purmah et al. 202118 | <40% (CMR) | Broad cardiovascular disease population, mean LVEF 55% | 7131 | Median 2.48 years | RVSD was associated with unadjusted HR of 3.1 for MACE, however it was not statistically significant after adjusting for LVEF |
| Ashcroft et al. 20216 | <46.9% (3D echocardiography) | Patients admitted with acute HF | 418 | Median 2 years | RVSD was associated with increased risk of ACM (HR 1.48; 95% CI 1.09–2.03, P ≤ 0.01) |
| Becker et al. 202112 | <45% (CMR) | Stable patients with dilated cardiomyopathy, mean LVEF 37% [25–44%] | 216 | Median 2.2 years | RVSD was significantly associated with shorter time to the composite of death and ventricular arrhythmias (10% drop in RVEF was associated with 0.81 increase in aHR, P = 0.02) |
| Kanagala et al. 202119 | <47% (CMR) | Chronic HFpEF patients compared against healthy controls | 183 | Median 4 years | RVSD was a strong independent predictor of HFH/ACM (aHR = 3.95, 95% CI: 1.88–8.29, P < 0.001) |
| Study/year . | RVSD definition cut-off-modality . | population . | n . | follow-up . | Main finding . |
|---|---|---|---|---|---|
| Larose et al. 20074 | <40% (CMR) | Patients with recent myocardial infarction (>30 days) | 147 | Median 17 months | RVEF <40% remained a significant independent predictor of mortality after adjusting for LVEF and infarct size (aHR 2.86; P = 0.03) |
| Meyer et al. 20102 | Multiple cut-offs: <40, <30, <20 (Radionuclide ventriculography) | Chronic HFrEF patients from ‘BEST’ trial | 2008 | Mean 2 years | RVSD was independently associated with mortality only at the cut-off <20%, aHR 1.32 (1.02 to 1.71; P = 0.034) |
| Gulati et al. 20138 | <45% (CMR) | Chronic HFrEF patients with dilated NICM | 250 | Median 6.8 years | RVSD was an independent predictor of mortality or cardiac transplant (HR 3.90; 95% CI: 2.16–7.04; P < 0.01) |
| Murninkas et al. 20149 | <38% (Radionuclide angiography) | Stable outpatient HFrEF cohort | 246 | Median 2.7 years | RVSD was not significantly associated with MACE or death after adjusting for LVEF and age |
| Goliasch et al. 201517 | <35% (CMR) | Chronic HFpEF patients | 142 | Median 10 months | RVSD was associated with hospitalization and cardiac death on univariate analysis, but not after adjusting for covariates. |
| Aschauer et al. 201615 | ≤45% (CMR) | Chronic HFpEF patients | 171 | Median 1.5 years | RVSD was an independent predictor of MACE (HR 4.90; 95% CI: 2.46–9.75; P < 0.01) |
| Mikami et al. 201710 | <45% (CMR) | Chronic HFrEF patients (ischaemic and non-ischaemic) | 314 | Median 2.1 years | RVSD was an independent predictor of cardiac arrest and/or ICD implantation (HR = 2.98; P = 0.002) |
| Gill et al. 201911 | <20% (CMR) | HFrEF patients with LVEF ≤35 | 87 | Median 3 years | RVSD was associated with a higher risk of MACE in the NICM subgroup but not ICM subgroup. |
| Purmah et al. 202118 | <40% (CMR) | Broad cardiovascular disease population, mean LVEF 55% | 7131 | Median 2.48 years | RVSD was associated with unadjusted HR of 3.1 for MACE, however it was not statistically significant after adjusting for LVEF |
| Ashcroft et al. 20216 | <46.9% (3D echocardiography) | Patients admitted with acute HF | 418 | Median 2 years | RVSD was associated with increased risk of ACM (HR 1.48; 95% CI 1.09–2.03, P ≤ 0.01) |
| Becker et al. 202112 | <45% (CMR) | Stable patients with dilated cardiomyopathy, mean LVEF 37% [25–44%] | 216 | Median 2.2 years | RVSD was significantly associated with shorter time to the composite of death and ventricular arrhythmias (10% drop in RVEF was associated with 0.81 increase in aHR, P = 0.02) |
| Kanagala et al. 202119 | <47% (CMR) | Chronic HFpEF patients compared against healthy controls | 183 | Median 4 years | RVSD was a strong independent predictor of HFH/ACM (aHR = 3.95, 95% CI: 1.88–8.29, P < 0.001) |
| Study/year . | RVSD definition cut-off-modality . | population . | n . | follow-up . | Main finding . |
|---|---|---|---|---|---|
| Larose et al. 20074 | <40% (CMR) | Patients with recent myocardial infarction (>30 days) | 147 | Median 17 months | RVEF <40% remained a significant independent predictor of mortality after adjusting for LVEF and infarct size (aHR 2.86; P = 0.03) |
| Meyer et al. 20102 | Multiple cut-offs: <40, <30, <20 (Radionuclide ventriculography) | Chronic HFrEF patients from ‘BEST’ trial | 2008 | Mean 2 years | RVSD was independently associated with mortality only at the cut-off <20%, aHR 1.32 (1.02 to 1.71; P = 0.034) |
| Gulati et al. 20138 | <45% (CMR) | Chronic HFrEF patients with dilated NICM | 250 | Median 6.8 years | RVSD was an independent predictor of mortality or cardiac transplant (HR 3.90; 95% CI: 2.16–7.04; P < 0.01) |
| Murninkas et al. 20149 | <38% (Radionuclide angiography) | Stable outpatient HFrEF cohort | 246 | Median 2.7 years | RVSD was not significantly associated with MACE or death after adjusting for LVEF and age |
| Goliasch et al. 201517 | <35% (CMR) | Chronic HFpEF patients | 142 | Median 10 months | RVSD was associated with hospitalization and cardiac death on univariate analysis, but not after adjusting for covariates. |
| Aschauer et al. 201615 | ≤45% (CMR) | Chronic HFpEF patients | 171 | Median 1.5 years | RVSD was an independent predictor of MACE (HR 4.90; 95% CI: 2.46–9.75; P < 0.01) |
| Mikami et al. 201710 | <45% (CMR) | Chronic HFrEF patients (ischaemic and non-ischaemic) | 314 | Median 2.1 years | RVSD was an independent predictor of cardiac arrest and/or ICD implantation (HR = 2.98; P = 0.002) |
| Gill et al. 201911 | <20% (CMR) | HFrEF patients with LVEF ≤35 | 87 | Median 3 years | RVSD was associated with a higher risk of MACE in the NICM subgroup but not ICM subgroup. |
| Purmah et al. 202118 | <40% (CMR) | Broad cardiovascular disease population, mean LVEF 55% | 7131 | Median 2.48 years | RVSD was associated with unadjusted HR of 3.1 for MACE, however it was not statistically significant after adjusting for LVEF |
| Ashcroft et al. 20216 | <46.9% (3D echocardiography) | Patients admitted with acute HF | 418 | Median 2 years | RVSD was associated with increased risk of ACM (HR 1.48; 95% CI 1.09–2.03, P ≤ 0.01) |
| Becker et al. 202112 | <45% (CMR) | Stable patients with dilated cardiomyopathy, mean LVEF 37% [25–44%] | 216 | Median 2.2 years | RVSD was significantly associated with shorter time to the composite of death and ventricular arrhythmias (10% drop in RVEF was associated with 0.81 increase in aHR, P = 0.02) |
| Kanagala et al. 202119 | <47% (CMR) | Chronic HFpEF patients compared against healthy controls | 183 | Median 4 years | RVSD was a strong independent predictor of HFH/ACM (aHR = 3.95, 95% CI: 1.88–8.29, P < 0.001) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
